Thilo Sprenger, Lena-Christin Conradi, Tim Beissbarth, Heiko Ermert, Kia Homayounfar, Peter Middel, Josef Rüschoff, Hendrik A. Wolff, Philipp Schüler, B. Michael Ghadimi, Claus Rödel, Heinz Becker, Franz Rödel and Torsten Liersch Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival Cancer 119
Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27703
The authors study the impact of CD133 (cluster of differentiation 133; a transmembrane glycoprotein also known as Prominin or PROM1) expression levels in pretreatment and post-treatment tumor specimens from 126 patients with locally advanced rectal cancers undergoing multimodal therapy with preoperative radiochemotherapy (RCT) and curative surgery. The results demonstrate that an enrichment of CD133-expressing cancer cells during RCT, and not absolute CD133 expression levels before and after RCT, can identify patients who are at higher risk of distant relapse and poor survival and may qualify for intensified after-care programs and adjuvant therapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field